Cancer Mutation Detection with Digital PCR - Summary - MDSpire
Feature

Cancer Mutation Detection with Digital PCR

Evaluating rapid assays for the detection of somatic mutations in tissue and liquid biopsies

  • April 15, 2026

  • 9 min

Share

Digital PCR (dPCR) has revolutionized oncological diagnostics, offering rapid screening for mutations and minimal residual disease monitoring. In a presentation by Dr. Valentina De Pascale from IRCCS Regina Elena National Cancer Institute, validation studies for dPCR assays targeting TERT and KRAS mutations were discussed, showcasing 100% concordance with reference methods in patient samples. dPCR's capabilities in detecting mutations in difficult samples make it a promising tool for precision oncology, potentially transforming routine diagnostic workflows in the future.

Original Source(s)

Cancer Mutation Detection with Digital PCR

  • April 15, 2026

Related Content

Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

From Spectra to Structure: An Interview with Novogaia’s Tess Bevers

Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery

Mass Spec Roundup: From Masterpieces to Microplastics

Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment

  • April 15, 2026

  • 6 min